#Israel #AstraZeneca #Compugen #Holon #COM701

Compugen's Advancements in Cancer Research and Quarterly Results

On May 18, 2026, Compugen Ltd. (NASDAQ: CGEN) released its first quarter results for 2026, showcasing significant strides in its development of cancer therapies and the company's financial health. The leadership, represented by President and CEO Eran Ophir, expressed optimism about the company’s ongoing projects, particularly the COM701 trial aimed at treating ovarian cancer.

COM701 MAIA-Ovarian Trial Update

The COM701 MAIA-ovarian trial is currently enrolling patients across clinical sites located in the U.S., Israel, and France. This trial serves as a critical component in evaluating COM701 as a maintenance therapy for patients suffering from ovarian cancer, a demographic with considerable unmet medical needs and no established standard of care. Dr. Ophir indicated that results from an interim analysis are expected by the first quarter of 2027, marking a pivotal point in the trial's progress.

This initiative reflectsCompugen's commitment to advancing cancer immunotherapy through innovative research and development. The company is employing its AI-driven computational discovery platform, Unigen™, to identify new drug targets, thereby expediting the development of treatments directed at enhancing the immune response against cancer cells.

Collaborations with Major Pharmaceutical Partners

In partnership with AstraZeneca, Compugen is also making significant strides in its work on rilvegostomig, a bispecific antibody considered essential in cancer immunotherapy. AstraZeneca is currently overseeing 11 Phase 3 clinical trials for this product and has recently shared promising data at the AACR 2026 conference, underlining their confidence in the drug’s differentiated design.

Moreover, Compugen's ongoing collaboration with Gilead, particularly with the GS-0321 Phase 1 trial, continues to advance as planned. These strategic partnerships underscore Compugen's role in forging significant alliances within the pharmaceutical industry, which could lead to substantial milestone payments and royalties.

Financial Health and Projections

Financially, Compugen reported approximately $134.9 million in cash and cash equivalents as of March 31, 2026. This solid financial foundation is projected to sustain operations through to 2029, assuring investors and stakeholders of the company’s longevity and the potential for continued innovation. Despite recording a net loss of about $7.7 million for the quarter, the loss per share remained consistent with the previous year, highlighting the company’s stability amidst its growth phase.

Research and development expenses totaled $6.9 million, an increase attributed mainly to the costs associated with the clinical trials. This investment is vital for the advancement and success of their drug development pipeline.

Future Outlook

Compugen’s strategic focus on immuno-oncology remains central to its mission. The company is not only committed to enhancing its existing pipeline but is also exploring novel methods to activate the immune system targeting different cancers. With a varied portfolio, including programs such as COM902, alongside COM701, the company is positioned to drive impactful changes in how cancer treatments are developed and administered.

Dr. Ophir is encouraged by the achievements thus far and has reinforced the company's dedication to leading advancements in immunotherapy. With partnerships valued at around $1 billion in potential milestones, Compugen's future in the oncology landscape appears promising.

In summary, Compugen Ltd. reports a productive quarter, with strategic collaborations and ongoing clinical efforts panning out well. The release of their Q1 results illustrates a landscape of significant advancements and a roadmap promising for stakeholders, investors, and ultimately, cancer patients.